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May 20111454 Letters to the EditorI take issue with a point made by the authors twice within their
Discussion. Their assertion that clopidogrel reduces the failure rate
of prosthetic grafts to approximate that of venous grafts is un-
founded. This comparison simply cannot be made in their study in
a statistically valid fashion. Patients in the CASPAR trial were not
randomized to conduit; hence, it is highly likely that those patients
who received venous vs prosthetic grafts differed significantly in
key clinical and anatomic variables. The authors did not share the
relevant characteristics of the two conduit subgroups in the report.
Multiple high quality randomized trials have demonstrated the
clear superiority of venous over prosthetic grafts for LEB, even in
the above-knee position.3 The implication that clopidogrel treat-
ment might alter this established paradigm is not substantiated by
their trial, and I think highly speculative.
In comparing the data fromCASPARandbypass versus angioplasty
in severe ischemia of the leg (BASIL)4 to that from North American
studies suchasProjectorEx-VivoveingraftEngineeringviaTransfection
(PREVENT) III,5 I am struck by two persistent observations. Despite
the fact that two-thirdsof thepatients in theCASPARtrialpresentedwith
symptoms of critical ischemia, only 25% of the LEBs performed in this
study were at a tibial or pedal level. In BASIL roughly one-third of the
grafts performed were infrapopliteal, whereas in PREVENT III the
proportion was reversed (two-thirds were tibial/pedal). Therefore, I
question if the results from these trials are relevant to patients requiring
infrapopliteal bypass surgery, which appears more common in current
surgical practice on this side of the Atlantic, particularly in the endovas-
cular era. Finally, all of these trials continue to demonstrate inadequate
medical therapy in LEBpatients, specifically the lowutilization of statins,
whichwere associatedwith abeneficial effect in theCASPARtrial, aswell
as in PREVENTIII.6 Perhaps an intensive-dose statin trialmay still be of
relevance in the LEB population?
Michael S. Conte, MD
University of California San Francisco
San Francisco, Calif
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Reply
Thank you for the opportunity to comment on Dr Conte’s
letter, which asks some key questions. Dr Conte comments on the
randomization of patients a few days after the operation. The main
purpose of this study was to examine the benefits of treatment
without increasing the risk of bleeding. Although it could be
i
argued that as thrombus formation can occur intra-operatively
reatment should be started immediately, or indeed pre-surgery,
o one had previously explored the use of two potent antiplatelet
gents in these surgical patients. The decision was therefore taken
o initiate treatment a few days after surgery to ensure hemostasis at
he operation site. Patients were not excluded for reasons other
han protocol exclusion criteria.
Unfortunately, the point about the site of occlusion possibly
eing different between prosthetic and venous grafts cannot be
xplored, as the graft failure endpoint did not require details of the
cclusion site to be documented.
In this study, clopidogrel appeared to reduce prosthetic graft occlu-
ion to a rate found in patients undergoing venous grafting. Dr Conte is
orrect, however, that as randomization toprosthetic or venous graftwas
ot a function of this trial, these two sets of patients are not comparable.
hus, it ismore correct to state that although theocclusion rate appeared
o be reduced to the level seen in this trial’s venous graft group, further
nvestigation is required to confirm this finding.
Regarding the geographic inequality of distal grafts between the
hree trials mentioned in paragraph two, we recruited throughout Eu-
ope from one of the largest surgical trials of clopidogrel, and the distri-
ution was as reported. It may be that in PREVENT III (Project or
x-vivo Vein graft ENgineering via Transfection III) a selection bias for
hemoredistal graft patients probably reflected the fact that venousgrafts
studied in PREVENT III) aremuch preferred for the distal graft site. It
s thus possible that PREVENT III had a selection bias toward themore
istal grafts, rather thanCASPAR(Clopidogrel andAcetylsalicylic acid in
ypass Surgery forPeripheralARterial disease) andBASIL (Bypass versus
ngioplasty in Severe Ischaemia of the Leg) having a selection bias
gainst.
The writer’s observation regarding a statin trial is interesting.
e have tried to garner interest from pharmaceutical companies in
his hypothesis; however, it would necessitate bringing all patients
nto treatment and then providing more aggressive treatment to
he “active group.” The numbers required for such a study appar-
ntly seemed prohibitive to the companies. Interestingly, after our
ecent study of a gene therapy in clopidogrel, similar global statin
reatment rates were observed 5 years on from the CASPAR trial.1
his reflects the fact that peripheral artery disease remains the poor
an of cardiovascular disease: underdiagnosed and undertreated.
ill J. F. Belch, MD, FRCP
nstitute of Cardiovascular Research
niversity of Dundee, Ninewells Hospital
undee, Scotland, United Kingdom
ohn Dormandy, MD, FRCS
ice Chairman
t George’s Hospital
ondon, United Kingdom
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emperature measurements for dose-finding in steam
blation
We very recently demonstrated the safety and efficacy of steam
blation for varicose veins in sheep and humans in a pilot study.1
he effectiveness of endovenous thermal ablative treatments (us-
ng laser, radio frequency of steam) depends primarily on the
mount of energy delivered to the venous wall.2,3 Previously, it was
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Volume 53, Number 5 Letters to the Editor 1455estimated that one “puff of steam” in steam ablation equalled approx-
imately 56 J, suggesting that 1 to 2 puffs/cm of vein would be
sufficient to occlude the vein.1 However, in the first 20 patients
treated, 1 pulse/cm was not optimal, and the pulse dose was subse-
quently doubled. The objective of our experiment was to better
understand the heat profile induced by steam and to investigate the
heat induction of 1, 2, and 3 puffs/cm using steam ablation.
In a sealed glass beaker filled with demineralized water, anal-
ysis of the number of frames of a high-speed camera demonstrated
that a steam pulse of the Steam Vein Sclerosis system (CERMA SA,
Archamps, France) lasts 0.99 seconds. Also, using a balance with a
precision of 0.01 grams, we estimated that the water mass of one
steam pulse averaged 0.08 grams.
In an experimental setup previously used to study thermal effects of
endovenous laser ablation,4 we measured the temperature profiles in-
ducedby steamablationusing three thermocouples located in thewall of
the tube, 1 cm apart, and intratubular thermocouples fixed at the top,
bottom, and sides at 2-mmdistanceof the center of the catheter,which is
moving in the center of the tube. The main parameter controlling the
unsteady heat transfer process is the heat diffusivity, which is about 0.14
10–6 m2/s. The process of expansion and subsequent collapse and
segregationof inducedsteamisbecause theeffectofheat transfer through
the bounding wall is minimal. The tube had an inner diameter of 4 mm
and an outer diameter of 6 mm. Because of the fast spread of injected
steam in the vein, conclusions about differences between the number of
puffs given is likely to be comparable for other diameters.
Table. The mean maximum temperature rise (Tmax),
the actual maximum temperature (Tmax), and time
50°C (tden) at different distances and locations inside
the plastic tube for 1, 2, and 3 pulses/cm
Outcome
Distance from center steam catheter tip C,
mean  SD (mm)
2 3 4 5
1 pulse/cm
Tmax 16.7  3.3 3.0  0.4 2.1  0.2 1.6  0.2
Tmax 36.7  3.3 23.0  0.4 22.1  0.2 21.6  0.2
2 pulse/cm
Tmax 33.9  1.7 5.4  0.3 3.8  0.2 3.1  0.2
Tmax 53.9  1.7 25.4  0.3 23.8  0.2 23.1  0.2
3 pulse/cm
Tmax 47.6  4.4 6.9  0.3 4.8  0.3 4.2  0.3
Tmax 67.6  4.4 26.9  0.3 24.8  0.3 24.2  0.3
Circumferentially, distributed thermocouples at
2-mm distance from C
Top Bottom Lateral
1 pulse/cm
Tmax 20.9  4.1 16.5  2.4 12.7  3.3
Tmax 40.9  4.1 36.5  2.4 32.7  3.3
2 pulse/cm
Tmax 33.8  1.6 33.8  2.0 33.7  1.4
Tmax 53.8  1.6 53.8  2.0 53.7  1.4
3 pulse/cm
Tmax 47.0  4.3 47.4  4.7 48.3  4.1
Tmax 67.0  4.3 67.4  4.7 68.3  4.1
tden seconds
1 pulse/cm 0.0  0.0 0.0  0.0 0.0  0.0
2 pulse/cm 13.0  30.1 10.4  4.5 4.8  3.7
3 pulse/cm 29.0  7.5 27.3  8.1 24.0  10.0
SD, Standard deviation; Tmax, temperature rise in °C (mean  SD); Tmax,
maximal temperature – baseline is considered 20°C (mean  SD).The circumferential locations were selected to assess the ho-
mogeneity of the temperature distribution caused by the steam delivered through a catheter with two opposite holes. Each of the
easurements was repeated five times and presented as the mean
ith the standard deviation. The maximum temperature rise
Tmax) at the wall of the plastic tube was modest for one pulse and
ncreased considerably with increasing number of pulses per cen-
imeter (Table). One steam pulse/cm showed inhomogeneous
Tmax compared with 2 or 3 pulses/cm, for which the temperature
ise was similar at the top, bottom, and sides at 2-mm radial
istance from the steam catheter. At 1-mm distance outside the
ube, Tmax was 5°C. At 2-mm distance from the catheter, the
uration that the temperature was50°C, which induces denatur-
tion of collagen (tden) and Tmax was zero for 1 pulse/cm
Table). For 2 pulses/cm, the tden varied between locations but
as 10 seconds at the top and bottom, and for 3 pulses/cm, it
as20 seconds and more homogenous compared with 2 pulses.
ompared with endovenous laser ablation (940 nm; 20 W; 2
m/s), the Tmax was considerably lower, but the tden was longer
or steam ablation (data not shown).
The loss of homogeneity using 1 pulse/cm is due to increased
onvection of the liquid and migration of vapor bubbles. The
atheter releases the steam puffs at two opposite sites of the distal
nd. In a restricted area, the administered steam first expands
uickly and occupies the entire volume available in its vicinity,
eading to a homogenous heat distribution over the inner side of
he venous wall but not over the outer side.
In summary, these experiments suggest that the temperature
nduced by 1 steam pulse/cm is insufficient, whereas at least 2
ulses/cm seems adequate to ablate varicose veins.
eter W. M. van Ruijven, MSc
epartment of Mechanical Engineering
indhoven University of Technology
indhoven, The Netherlands
enate Ruth van den Bos, MD
epartment of Dermatology
rasmus Medical Center
otterdam, The Netherlands
ucie M. Alazard, MSc
ees W. M. van der Geld, PhD
epartment of Mechanical Engineering
indhoven University of Technology
indhoven, The Netherlands
amar Nijsten, MD, PhD
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May 20111456 Letters to the EditorRegarding “Prospective randomized trial comparing
endovenous laser ablation and surgery for treatment
of primary great saphenous varicose veins with a
2-year follow-up”
As authors of a systematic review on the treatment of
varicose veins, we closely scrutinized the recent publication by
Christenson et al1 for potential inclusion. Christenson et al
randomized the treatment of 200 limbs with primary varicose
veins to receive conventional surgery or endovenous laser abla-
tion.
The primary outcome measure was closure of the great
saphenous vein. Secondary outcome measures included general
health quality of life measures (Short Form 36) and disease-
specific measures (Aberdeen Varicose Vein Symptom Severity
Score and Venous Clinical Severity Score). Postoperative com-
plications, time to return to normal activity, and pain scores
(mean use of analgesics and a visual analog scale score) were
noted.
After contacting the corresponding author, we confirmed that
40 patients underwent treatment of bilateral varicose veins, al-
though this was not clear from the article itself. All patients with
bilateral varicose veins were treated on the same day. We also
confirmed that patient’s limbs were randomized, not the patients
themselves. In fact, eight patients underwent surgery on one limb
and laser treatment on the other on the same day.
Clear biases result from this methodology, especially regard-
ing the postoperative quality of life scores. The high proportion of
bilaterally treated patients also affects pain scores. Time to return
to work is also published, but limbs cannot return to work inde-
pendently of one another. Trials that randomize and analyze
results according to number of limbs rather than the number of
patients as the unit of analysis result in the standard error of the
treatment effect being much smaller than it should be.
The shortcomings in this trial mean that the results must be
taken with caution. Greater effort must be made in the future to
publish trial data with greater transparency, and future trialists
must heed the pitfall of randomizing patients’ limbs rather than the
patients themselves. Investigators must give further thought on
how to approach the problems of including, randomizing, and
Table. Outcome comparison between high ligation and st
ablation of primary great saphenous varicose veins at 2-yea
after exclusion of patients with bilateral treatment
Variables
Results presented in
HL/S n  100
limbs P
Limbs lost 1 .212
Limbs analyzed 99 .212
Primary end points
GSV absent/completely closed 99 1.0
GSV completely reopened 0 —
GSV partially reopened 0 —
GSV completely  partially
reopened or detectable 0 .051
Reflux 2 .050
Limbs with symptoms 1 .007
GSV, Great saphenous vein.
aChristenson JT, Gueddi S, Gemayel G, Bounameaux H. Prospective rand
primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surgtreating patients with bilateral disease. draig Iain Nesbitt, MBChB, MRCSed
erard Stansby, MA (Catab), MB, M.Chir, FRCS
ascular Surgery
reeman Hospital
ewcastle upon Tyne, United Kingdom
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eply
The point raised by this reader is well taken, and we agree that
ome aspects of the postoperative quality of life might be affected by
hemethodology used.However, ruling out the 40 patients (58 limbs
n the surgical arm and 62 in the endovenous laser arm) who under-
ent bilateral treatment did not affect the overall results (Table). In
ddition, the Aberdeen Varicose Vein Symptom Severity Score and
enous Clinical Severity Score did not change, and there were no
ignificant changes in Short Form 36 scores when the bilaterally
reated patients were excluded from the analysis compared with when
heywere included and presented in our article. This does not rule out
ut at least attenuates the reader’s concern.
an T. Christenson, MA, MD, PhD, PD
ivision of Cardiovascular Surgery
enus Surgery Centre
niversity Hospital of Geneva
eneva, Switzerland
enri Bounameaux, MD
ervice of Angiology and Hemostasis
niversity Hospital of Geneva
eneva, Switzerland
ng (HL/S) and endovenous laser treatment (EVLT) for
llow-up comparing results as presented in the articlea and
rticle Results after exclusion of bilat treatment
VLT n  100
limbs
HL/S n  58
limbs/patients P
EVLT n  62
limbs/patients
5 0 .496 2
95 58 .496 60
88 58 1.0 54
2 0 — 2
5 0 — 4
7 0 .027 6
8 0 .013 7
9 0 .006 8
d trial comparing endovenous laser ablation and surgery for treatment of
;52:1234-41.rippi
rs’ fo
the a
Eoi:10.1016/j.jvs.2011.01.005
